Home › Compare › LMDX vs RYLD

LMDX vs RYLD: Dividend Comparison 2026

LMDX yields 12500.00% · RYLD yields 12.14%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 LMDX wins by $498747976996367872.00M in total portfolio value
10 years
LMDX
LMDX
● Live price
12500.00%
Share price
$0.02
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$498747976996367872.00M
Annual income
$491,020,681,003,619,800,000,000.00
Full LMDX calculator →
RYLD
RYLD
● Live price
12.14%
Share price
$14.95
Annual div
$1.81
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$44.5K
Annual income
$2,587.35
Full RYLD calculator →

Portfolio growth — LMDX vs RYLD

📍 LMDX pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodLMDXRYLD
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, LMDX + RYLD cover 0 of 12 months — good coverage

Jan
—
Feb
—
Mar
—
Apr
—
May
—
Jun
—
Jul
—
Aug
—
Sep
—
Oct
—
Nov
—
Dec
—
LMDX pays
RYLD pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

LMDX
Annual income on $10K today (after 15% tax)
$1,062,500.00/yr
After 10yr DRIP, annual income (after tax)
$417,367,578,853,076,800,000,000.00/yr
RYLD
Annual income on $10K today (after 15% tax)
$1,031.60/yr
After 10yr DRIP, annual income (after tax)
$2,199.25/yr
At 15% tax rate, LMDX beats the other by $417,367,578,853,076,800,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of LMDX + RYLD for your $10,000?

LMDX: 50%RYLD: 50%
100% RYLD50/50100% LMDX
Portfolio after 10yr
$249373988498183936.00M
Annual income
$245,510,340,501,809,900,000,000.00/yr
Blended yield
98.45%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on LMDX right now

LMDX
Analyst Ratings
3
Buy
1
Hold
Consensus: Buy
Price Target
$1.50
+9275.0% upside vs current
Range: $1.50 — $1.50
Altman Z
-8.0
Piotroski
2/9
RYLD
No analyst data
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

LMDX buys
0
RYLD buys
0
No recent congressional trades found for LMDX or RYLD in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricLMDXRYLD
Forward yield12500.00% ✓12.14%
Annual dividend / share$2.00 ✓$1.81
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%0%
Portfolio after 10y$498747976996367872.00M ✓$44.5K
Annual income after 10y$491,020,681,003,619,800,000,000.00 ✓$2,587.35
Total dividends collected$498235517183739840.00M ✓$18.8K
Payment frequencyquarterlyquarterly
SectorStockETF

Year-by-year: LMDX vs RYLD ($10,000, DRIP)

YearLMDX PortfolioLMDX Income/yrRYLD PortfolioRYLD Income/yrGap
1← crossover$1,260,700$1,250,000.00$11,914$1,213.65+$1.25M → LMDX
2$148,626,986$147,278,037.38$14,099$1,351.30+$148.61M → LMDX
3$16,386,101,622$16,227,070,746.70$16,580$1,494.55+$16386.09M → LMDX
4$1,689,525,624,319$1,671,992,495,582.84$19,384$1,642.61+$1689525.60M → LMDX
5$162,924,168,596,046$161,116,376,178,025.50$22,535$1,794.70+$162924168.57M → LMDX
6$14,694,663,924,503,782$14,520,335,064,106,012.00$26,063$1,950.00+$14694663924.48M → LMDX
7$1,239,682,670,110,485,000$1,223,959,379,711,266,000.00$29,995$2,107.69+$1239682670110.46M → LMDX
8$97,827,968,310,781,350,000$96,501,507,853,763,130,000.00$34,361$2,266.99+$97827968310781.31M → LMDX
9$7,221,771,955,839,384,000,000$7,117,096,029,746,848,000,000.00$39,194$2,427.12+$7221771955839384.00M → LMDX
10$498,747,976,996,367,840,000,000$491,020,681,003,619,800,000,000.00$44,525$2,587.35+$498747976996367872.00M → LMDX

LMDX vs RYLD: Complete Analysis 2026

LMDX — Stock

LumiraDx Limited operates as a point of care diagnostics company. The company focuses on transforming community-based healthcare by providing critical diagnostic information to healthcare providers. It manufactures and commercializes a diagnostic platform that supports various tests with lab comparable performance at the point of care. The company has approximately 30 tests on the market and in development covering infectious diseases, cardiovascular diseases, diabetes, and coagulation disorders, as well as a portfolio of COVID-19 testing solutions from the lab to point of need. Its diagnostic testing solutions are deployed by governments and healthcare institutions across laboratories, urgent care, physician offices, pharmacies, schools, and workplaces to screen, diagnose, and monitor wellness, as well as disease. The company was founded in 2014 and is headquartered in London, the United Kingdom.

Full LMDX Calculator →

RYLD — ETF

The Global X Russell 2000 Covered Call ETF (RYLD) seeks to provide investment results that correspond generally to the price and yield performance, before fees and expenses, of the Cboe Russell 2000 BuyWrite Index.

Full RYLD Calculator →
📬

Get this LMDX vs RYLD comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

LMDX vs SCHDLMDX vs JEPILMDX vs OLMDX vs KOLMDX vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.